Tags

Type your tag names separated by a space and hit enter

Protracted fecal shedding of HEV during ribavirin therapy predicts treatment relapse.
Clin Infect Dis. 2015 Jan 01; 60(1):96-9.CI

Abstract

Twenty-four solid-organ-transplant recipients with chronic hepatitis E virus (HEV) infections were given ribavirin therapy for 3 months. All the patients with protracted fecal HEV shedding during treatment suffered a relapse. Monitoring HEV fecal excretion could be used to determine the optimal duration of ribavirin therapy.

Authors+Show Affiliations

INSERM, U1043, Centre de Physiopathologie de Toulouse Purpan CHU Toulouse, Hôpital Purpan, Laboratoire de virologie, Centre National de Référence Hépatite E, Institut fédératif de biologie de Purpan.INSERM, U1043, Centre de Physiopathologie de Toulouse Purpan CHU Toulouse, Hôpital Purpan, Laboratoire de virologie, Centre National de Référence Hépatite E, Institut fédératif de biologie de Purpan.INSERM, U1043, Centre de Physiopathologie de Toulouse Purpan CHU Toulouse, Hôpital Rangueil, Service de Néphrologie, Dialyse et Transplantation multi-organe, France.INSERM, U1043, Centre de Physiopathologie de Toulouse Purpan CHU Toulouse, Hôpital Rangueil, Service de Néphrologie, Dialyse et Transplantation multi-organe, France.INSERM, U1043, Centre de Physiopathologie de Toulouse Purpan CHU Toulouse, Hôpital Purpan, Laboratoire de virologie, Centre National de Référence Hépatite E, Institut fédératif de biologie de Purpan.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

25249523

Citation

Abravanel, Florence, et al. "Protracted Fecal Shedding of HEV During Ribavirin Therapy Predicts Treatment Relapse." Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, vol. 60, no. 1, 2015, pp. 96-9.
Abravanel F, Lhomme S, Rostaing L, et al. Protracted fecal shedding of HEV during ribavirin therapy predicts treatment relapse. Clin Infect Dis. 2015;60(1):96-9.
Abravanel, F., Lhomme, S., Rostaing, L., Kamar, N., & Izopet, J. (2015). Protracted fecal shedding of HEV during ribavirin therapy predicts treatment relapse. Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, 60(1), 96-9. https://doi.org/10.1093/cid/ciu742
Abravanel F, et al. Protracted Fecal Shedding of HEV During Ribavirin Therapy Predicts Treatment Relapse. Clin Infect Dis. 2015 Jan 1;60(1):96-9. PubMed PMID: 25249523.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Protracted fecal shedding of HEV during ribavirin therapy predicts treatment relapse. AU - Abravanel,Florence, AU - Lhomme,Sébastien, AU - Rostaing,Lionel, AU - Kamar,Nassim, AU - Izopet,Jacques, Y1 - 2014/09/23/ PY - 2014/9/25/entrez PY - 2014/9/25/pubmed PY - 2015/9/1/medline KW - fecal shedding KW - hepatitis E virus KW - relapse KW - ribavirin therapy SP - 96 EP - 9 JF - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America JO - Clin Infect Dis VL - 60 IS - 1 N2 - Twenty-four solid-organ-transplant recipients with chronic hepatitis E virus (HEV) infections were given ribavirin therapy for 3 months. All the patients with protracted fecal HEV shedding during treatment suffered a relapse. Monitoring HEV fecal excretion could be used to determine the optimal duration of ribavirin therapy. SN - 1537-6591 UR - https://www.unboundmedicine.com/medline/citation/25249523/Protracted_fecal_shedding_of_HEV_during_ribavirin_therapy_predicts_treatment_relapse_ L2 - https://academic.oup.com/cid/article-lookup/doi/10.1093/cid/ciu742 DB - PRIME DP - Unbound Medicine ER -